Introduction
============

The gut lumen contains a very complex mixture of compounds from alimentary and endogenous origins together with living microorganisms. The intestinal microbiota is metabolically active and plays a significant role in host physiology and metabolism ([@B14]). The ability to metabolize peptides and amino acids is shared by a large number of bacteria ranging from saccharolytic bacteria to obligate amino acid fermenters present in gut microbiota ([@B7]). Peptides are the preferred substrates over free amino acids for many colonic bacteria, probably due to kinetic advantages of peptide uptake systems. Moreover, nitrogen source, such as amino acids, are fermented to short-chain fatty acids and organic acids, representing energy fuel for the colonic mucosa ([@B7]).

Milk proteins and peptides such as lactoferrin, lactoperoxidase, and lysozyme are reported to provide a non-immune defense against microbial infections ([@B31]). In addition, they are known to stimulate growth of several members of the human infant microbiota such *Lactobacillus* and *Bifidobacterium* ([@B17]; [@B23]). In this latter ecological context, the bacterial population is dominated by bifidobacteria, which remain a prominent component of the gut microbiota until weaning ([@B35]; [@B8]; [@B39]). Member of the genus *Bifidobacterium* are anaerobic microorganisms, typically resident in the gastro intestinal tract of mammals and insects ([@B20]), where they are known to interact with their hosts using various genetic strategies ([@B27]; [@B10]; [@B41]; [@B38]).

Among host-derived nutrients, milk proteins significantly influence the composition of the gut microbiota, supplying these microorganisms with nitrogen and amino acids ([@B17]). Enhancement of (bifido)bacterial growth is frequently associated with milk proteins and the peptides that arise from the hydrolysis of these proteins ([@B26]; [@B19]).

Compared to carbon metabolism, for which a large body of scientific data is available ([@B30]; [@B22]), only very limited knowledge is available on the acquisition and assimilation processes that are used by members of the infant gut microbiota to retrieve nitrogen from the gut lumen ([@B17]). For Gram positive bacteria, nitrogen metabolism has been investigated in *Lactobacillus delbrueckii* subsp. *bulgaricus* ([@B18]), *Lactobacillus rhamnosus* ([@B16]) and *Bacillus* sp. ([@B12]; [@B9]).

Recently, specific interest has been directed toward sulfur-containing amino acids and global control of cysteine and methionine metabolism in both Gram positive and negative bacteria, such as *Lactococcus lactis*, *Salmonella* sp., *Vibrio fischeri* and *Clostridium perfringens* ([@B11]; [@B2]; [@B1]; [@B32]). Cysteine biosynthesis is the key mechanism by which inorganic sulfur is reduced and incorporated into organic compounds ([@B15]), where it plays an essential role in the formation of the catalytic sites of several enzymes, or protein folding and assembly via the formation of disulfide bonds ([@B24]). Sulfur-containing compounds that are used for the synthesis of cysteine and methionine are transported into the bacterial cell through different mechanisms: the first involves sulfate permease related to inorganic phosphate transporters (CysC) and then the reduction of sulfate to sulfide ([@B21]) (**Figure [1](#F1){ref-type="fig"}**). The second involves aliphatic sulfonate ATP-binding cassette (ABC) transporters (SsuBD) ([@B40]) and the subsequent conversion into sulfide by an FMNH monooxygenase (**Figure [1](#F1){ref-type="fig"}**). The following reaction of sulfide with *O*-acetyl-[L]{.smallcaps}-serine (OAS) results in cysteine synthesis by the action of an *O*-acetylserine thiol-lyase ([@B3]). Alternatively, cysteine can be directly transported inside the cell by symporter proteins (TcyBCP) ([@B4]). Methionine biosynthesis is closely linked to cysteine production by the action of serine acetyltransferase, which uses cysteine and an *O*-acetylhomoserine to generate cystathionine, where the latter compound is then converted to homocysteine and methionine ([@B11]) (**Figure [1](#F1){ref-type="fig"}**).

![**Schematic representation of the metabolic pathways for sulfur amino acid in Gram positive bacteria.** The different ORFs of *Bifidobacterium bifidum* PRL2010 encoding the predicted enzymes are indicated. The metabolic steps present in Gram positive bacteria but absent in PRL2010 (sulfate assimilation and glutathione synthesis) are indicated by gray arrows. Molecule involved are reported as follow: serine Ser, *O*-acetyl-[L]{.smallcaps}-serine OAS, cysteine Cys, homoserine hSer, *O*-succinylhomoserine *O*-ShSer, cystathionine Cyst, homocysteine hCys and methionine Met.](fmicb-06-01331-g001){#F1}

In this study, in order to understand the role of the bifidobacterial population in the utilization of nitrogen available in the human gut, we evaluated the amino acid metabolism of the infant stool isolate *B. bifidum* PRL2010 (LMG S-28692), a bifidobacterial prototype for analysis of interactions between microbes and the intestinal mucosa ([@B37]), by coupling physiological data on a chemically defined medium (CDM) with transcriptional analysis. Specific emphasis was placed on sulfur amino acids/metabolism of PRL2010 since these amino acids are particularly important for the bacterial cells of gut commensals in coping against gut related stresses (e.g., oxidative stress) ([@B9]).

Furthermore, PRL2010 metabolism of complex substrates from milk such as casein hydrolysate and whey proteins was investigated.

Materials and Methods {#s1}
=====================

Bacterial Strains and DNA Extraction
------------------------------------

Bifidobacterial strains used in this study are reported in **Table [1](#T1){ref-type="table"}**. Strains were grown anaerobically in de Man, Rogosa, Sharpe (MRS) medium (Scharlau, Spain), which was supplemented with 0.05% [L]{.smallcaps}-cysteine-HCl and incubated at 37°C for 16 h. Anaerobic conditions were achieved by the use of an anaerobic cabinet (Ruskin), in which the atmosphere consisted of 10% CO~2~, 80% N~2~, and 10% H~2~.

###### 

Bifidobacterial strains used in this study.

  Bacteria                                          Strains^a^            Genome accession numbers
  ------------------------------------------------- --------------------- --------------------------
  *B. actinocoloniiforme*                           DSM 22766             JGYK00000000
  *B. adolescentis*                                 ATCC 15703            AP009256.1
  *B. angulatum*                                    LMG 11039             JGYL00000000
  *B. animalis* subsp. *animalis*                   LMG 10508             JGYM00000000
  *B. animalis* subsp. *lactis*                     DSM 10140             CP001606.1
  *B. asteroides*                                   LMG 10735 (PRL2011)   CP003325.1
  *B. biavatii*                                     DSM 23969             JGYN00000000
  *B. bifidum*                                      LMG 11041             JGYO00000000
  *B. bifidum*                                      PRL2010               CP001840
  *B. bifidum*                                      85B                   JSDU00000000
  *B. bifidum*                                      324B                  JSDT00000000
  *B. bifidum*                                      156B                  JSDS00000000
  *B. bifidum*                                      LMG 11583             JSDZ00000000
  *B. bifidum*                                      LMG 11582             JSDY00000000
  *B. bifidum*                                      LMG 13200             JSEB00000000
  *B. bifidum*                                      LMG 13195             JSEA00000000
  *B. bohemicum*                                    DSM 22767             JGYP00000000
  *B. bombi*                                        DSM 19703             ATLK00000000
  *B. boum*                                         LMG 10736             JGYQ00000000
  *B. breve*                                        LMG 13208             JGYR00000000
  *B. callitrichos*                                 DSM 23973             JGYS00000000
  *B. catenulatum*                                  LMG 11043             JGYT00000000
  *B. choerinum*                                    LMG 10510             JGYU00000000
  *B. coryneforme*                                  LMG 18911             CP007287
  *B. crudilactis*                                  LMG 23609             JHAL00000000
  *B. cuniculi*                                     LMG 10738             JGYV00000000
  *B. dentium*                                      LMG 11405 (Bd1)       CP001750.1
  *B. gallicum*                                     LMG 11596             JGYW00000000
  *B. gallinarum*                                   LMG 11586             JGYX00000000
  *B. indicum*                                      LMG 11587             CP006018
  *B. kashiwanohense*                               DSM 21854             JGYY00000000
  *B. longum* subsp. *infantis*                     ATCC 15697            AP010889.1
  *B. longum* subsp. *longum*                       LMG 13197             JGYZ00000000
  *B. longum* subsp. *suis*                         LMG 21814             JGZA00000000
  *B. magnum*                                       LMG 11591             JGZB00000000
  *B. merycicum*                                    LMG 11341             JGZC00000000
  *B. minimum*                                      LMG 11592             JGZD00000000
  *B. mongoliense*                                  DSM 21395             JGZE00000000
  *B. moukalabense*                                 DSM 27321             AZMV00000000.1
  *B. pseudocatenulatum*                            LMG 10505             JGZF00000000
  *B. pseudolongum* subsp. *globosum*               LMG 11596             JGZG00000000
  *B. pseudolongum* subsp. *pseudolongum*           LMG 11571             JGZH00000000
  *B. psychraerophilum*                             LMG 21775             JGZI00000000
  *B. pullorum*                                     LMG 21816             JGZJ00000000
  *B. reuteri*                                      DSM 23975             JGZK00000000
  *B. ruminantium*                                  LMG 21811             JGZL00000000
  *B. saeculare*                                    LMG 14934             JGZM00000000
  *B. saguini*                                      DSM 23967             JGZN00000000
  *B. scardovii*                                    LMG 21589             JGZO00000000
  *B. stellenboschense*                             DSM 23968             JGZP00000000
  *B. stercoris*                                    DSM 24849             JGZQ00000000
  *B. subtile*                                      LMG 11597             JGZR00000000
  *B. thermacidophilum* subsp. *porcinum*           LMG 21689             JGZS00000000
  *B. thermacidophilum* subsp. *thermacidophilum*   LMG 21395             JGZT00000000
  *B. thermophilum*                                 JCM 1207              JGZV00000000
  *B. tsurumiense*                                  JCM 13495             JGZU00000000
                                                                          

a

ATCC, American Type Culture Collection, USA. LMG, Belgian Co-ordinated Collection of Microorganisms-Bacterial Collection, Belgium. DSM, German Collection of Microorganism and Cell Cultures, Germany. JCM, Japan Collection of Microorganisms, Japan.

*Bifidobacterium* CDM Development
---------------------------------

For amino acid auxotrophy and prototrophy tests, a CDM was employed based on a previously described formulation ([@B28]; [@B6]) for *Lactobacillus* and *Bifidobacterium*, with some modifications. Briefly, to the already reported CDM, 50 mg/l of guanine and 4.0 mg/l of thiamine was added. Several simple sugars were screened including glucose, fructose, galactose, lactose, ribose, xylose, fucose, mannose, and rhamnose. All carbohydrates were added at 2% (w/w). The medium was sterilized by filtration (0.22 μm). When the CDM was prepared without amino acids it is termed basal CDM (bCDM). All components of CDM were purchased from Sigma (USA).

Amino Acid and Nitrogen Growth Assay
------------------------------------

Cell growth on CDM was monitored by measuring the optical density of cultures at 600 nm (OD 600) using a plate reader (Biotek, Winooski, VT, USA). The plate reader was run in discontinuous mode, with absorbance readings performed after 24 h of incubation and preceded by 30 s of shaking at medium speed. Bacteria were cultivated in the wells of a 96-well microtiter plate, with each well containing a different amino acid, and incubated in an anaerobic cabinet.

For all growth tests, cells were recovered from an overnight MRS broth culture, centrifuged at 3000 rpm for 5 min in anaerobiosis, and washed with bCDM to remove protein and sugar residues. In each of the 96-wells of the microplate, 135 μl of medium was inoculated with 15 μl of washed cells diluted to OD 1.0 with bCDM, obtaining a final inoculum OD of 0.1. Wells were covered with 30 μl of sterile mineral oil in order to maintain anaerobic conditions. Cultures were grown in biologically independent triplicates and the resulting growth data were expressed as the means from these replicates.

Once it had been established that CDM supports bifidobacterial growth, amino acid assays were performed using CDM in which individual amino acids were omitted or with bCDM supplemented with 0.2 g/l of a particular amino acid. To understand amino acid metabolism and in particular the metabolism of sulfur-containing amino acids derived from complex substrates, bCDM was supplemented with 2--0.5% (w/w) of whey protein or casein hydrolysate (Sigma). To test the influence of reduced sulfur substrate instead cysteine to PRL2010 growth, 5 mM of reduced glutathione (Sigma) was added to bCDM formulation without any other amino acid (bCDM + Glut). To evaluate the utilization of source of sulfur and nitrogen available in the gut environment, 0.5 g/l of taurine was added to bCDM.

Identification of Genes Involved in Sulfur-containing Amino Acid Metabolism
---------------------------------------------------------------------------

The identification of genes involved in cysteine and methionine metabolism in PRL2010 and other *B. bifidum* strains was performed by using the BLASTP program ([@B13]). For the BLAST search, previously identified genes involved in sulfur metabolism of lactic acid bacteria were used ([@B18]). Twenty bp oligonucleotides for RT-qPCR experiments were manually designed on identified putative genes to obtain amplicons with a size ranging from 150 to 200 bp. Primers were checked with Primer Blast ([@B43]) and listed in **Table [2](#T2){ref-type="table"}**.

###### 

Primers used for RT-qPCR experiments.

  Target      ORF         Primer Fw 5′-3′   Primer Rv 5′-3′           Size (bp)                                
  ----------- ----------- ----------------- ------------------------- ------------- -------------------------- -----
  *cysE*      BBPR_1340   cysE-fw           CGCGACCATGCGCGACTACC      cysE-rv       GAGGATGCGCTCGTGTCCGC       187
  *cysK*      BBPR_1344   cysK-fw           CGAACCAGTACGACAACCCC      cysK-rv       GATGGAGCCTTCCGGATCGG       203
  *cysB*      BBPR_0960   cysB-fw           GACGACCTCAAGCCGTTCCC      cysB-rv       GTCGCCGTTGTCGATGCCGG       189
  *metB*      BBPR_1343   metB-fw           GGAGCCCGACCCGACCACCG      metB-rv       CAGCAGCACGTCAATCGCGG       214
  *metC*      BBPR_1226   metC-fw           CATGGGTGTGGGAAGCGAGG      metC-rv       TCGATGTCCCAGTTGTGCCG       189
  *metE*      BBPR_0933   metE-fw           GATGCTGGACACCGCGATCC      metE-rv       GGCGGATCTCGGTGCTCTCC       206
  *metA*      BBPR_1654   metA-fw           GTTCGCTCTCGGCCATTGGG      metA-rv       CGGCGTGGTCTGATACACCC       205
  *rpoB^a^*               BBP-rpo-for       GTGCAGACCGACAGCTTCGAC     BBP-rpo-rev   GAGATCTCGTTGAAGAACTCGTC    
  *ldh^a^*                BBP-ldh-for       CACCATGAACAGGAACAAAGTTG   BBP-ldh-rev   GAATGATCGATGAGTACGAGCTC    
  *atpD^a^*               BBP-atp-uni       CAGAGCCGATCAATGGACGTG     BBP-atp-rev   GTGCTGCTCGACCTCAAGCGTGAT   
                                                                                                               

a

Turroni et al. (2011)

.

RNA Isolation, Reverse Transcription and RT-qPCR
------------------------------------------------

Total RNA was isolated from PRL2010 cultures grown in CDM, bCDM supplemented with cysteine, or bCDM supplemented with cysteine and whey protein or casein hydrolysate (2% w/w). PRL2010 cells grown in MRS was used as a control condition. Cultures were grown in biologically independent triplicates. Cells were harvested by centrifugation step at 4000 ×*g* for 5′ at 4°C when cells had reached late exponential phase (OD values of 0.8--1.0, except for bCDM supplemented with glutathione where cells were harvested at OD 0.35). Cell pellets were resuspended in 500 μl of RNAprotect reagent (Qiagen, UK) and mechanically lysed by inclusion of 0.1 mm zirconium--silica beads (Biospec Products, Bartlesville, OK, USA) and by subjecting the sample to three 2 min pulses at maximum speed in a bead beater (Biospec Products, Bartlesville, OK, USA) with intervals of 3 min on ice. RNA was extracted with the RNeasy mini kit (Qiagen) as reported in the manufacturer's instructions. Quality and integrity of the RNA was checked by Tape station 2200 (Agilent Technologies, USA) analysis and only samples displaying a RIN value above seven were used. RNA concentration and purity was then determined with a Picodrop microlitre Spectrophotometer (Picodrop). Reverse transcription to cDNA was performed with the iScript Select cDNA synthesis kit (Biorad) using the following thermal cycle: 5 min at 25°C, 30 min at 42°C, 10 min at 45°C, 10 min at 50°C and 5 min at 85°C.

The mRNA expression levels of these genes were analyzed with SYBR green technology in quantitative real-time PCR (qRT-PCR) using SoFast EvaGreen Supermix (Biorad) on a Bio-Rad CFX96 system according to the manufacturer's instructions. Quantitative PCR was carried out according to the following cycle: initial hold at 96°C for 30 s and then 40 cycles at 96°C for 2 s and 60°C for 5 s. Gene expression was normalized relative to a housekeeping genes as previously described ([@B34]) and reported in **Table [2](#T2){ref-type="table"}**. The amount of template cDNA used for each sample was 12.5 ng.

Statistical Analyses
--------------------

Statistical significance between means was analyzed using the two way ANOVA. Statistically different means were determined using the Bonferroni *post hoc* test at 5% (*P*-value \< 0.05). Values are expressed as the means ± standard errors from three experiments. Statistical calculations were performed using the software program GraphPad Prism 5 (La Jolla, CA, USA).

Results
=======

Development of a CDM for *B. bifidum* PRL2010
---------------------------------------------

We modified the previously described CDM formulations ([@B28]; [@B6]) based on the nutrient requirements of *B. bifidum* PRL2010. Several growth attempts on CDM minimal modifications ([@B28]; [@B6]), i.e., where various compounds were omitted one after the other, allowed the identification of a number of components that were either essential or non-essential for growth of PRL2010 cells. Notably, folic acid and pyridoxal were eliminated from CDM~PRL2010~ composition, while guanine and thiamine were supplemented. When testing different sugars it was observed that PRL2010 exhibits the best growth performance with lactose, consistent with previous studies ([@B33], [@B36]), and this sugar was therefore used for CDM~PRL2010~ formulation.

Evaluation of Amino Acids Auxotrophy and Prototrophy of PRL2010
---------------------------------------------------------------

When PRL2010 cells were cultivated on CDM~PRL2010~, they exhibited reduced growth (OD600 value of 1.21 ± 0.3) compared to that observed when grown on a nutrient-rich medium such as MRS (OD600 value of 2.9 ± 0.2). In order to assess PRL2010 amino acid prototrophy/auxotrophy, growth experiments were performed using CDM~PRL2010~ where an individual amino acid had been omitted at time, and bCDM~PRL2010~ medium with the inclusion of one amino acid at time. The achieved growth yield was compared to that obtained for complete CDM~PRL2010~ or bCDM~PRL2010~ respectively (**Figure [2A](#F2){ref-type="fig"}**).

![**Growth of *B. bifidum* strains**. Growth was measured as the optical density of the medium at 600 nm (OD600). Cultures were grown in triplicates. **(A)** Reports the growth of *B. bifidum* PRL2010 in CDM~PRL2010~. In these tests, one amino acid at time was removed (CDM-AA) or supplied (bCDM + AA) to the medium. Amino acids are reported in the horizontal axis as follows: aspartic acid Asp, threonine Thr, leucine Leu, tryptophan Trp, valine Val, histidine His, serine Ser, arginine Arg, isoleucine Iso, methionine Met, lysine Lys, cysteine Cys, proline Pro, glutamine Gln, alanine Ala, glycine Gly, phenylalanine Phe and tyrosine Tyr. **(B)** Shows an heat map representing the growth performance of all of the type strains of the currently recognized 48 (sub)species belonging to the genus *Bifidobacterium* on CDM~PRL2010~, CDM-Cys~PRL2010~ and bCDM~PRL2010~. The different shading represents the optical density reached by the various cultures. **(C)** Displays the growth of *B. bifidum* strains LMG11041, 85B, 156B, 324B, LMG11583, LMG11582 LMG13200 and LMG13195 in comparison with PRL2010 in CDM~PRL2010~, CDM~PRL2010~ without cysteine (CDM -- Cys), basal CDM~PRL2010~ (bCDM), basal CDM~PRL2010~ with cysteine (bCDM + Cys) and basal CDM~PRL2010~ with glutathione (bCDM + Glut). **(D)** Illustrates the growth of *B. bifidum* PRL2010 in CDM~PRL2010~ supplemented with complex substrates like whey proteins or casein hydrolysate. For both substrates two concentration were tested, 0.5 and 2% (wt/wt). For every concentration was evaluated the presence of amino acid (CDM or bCDM) or other nitrogen sources (N or w/o N).](fmicb-06-01331-g002){#F2}

In both experiments, only when cysteine was removed or supplied to the medium a significant decrease or increase (ranging from four- to sixfold, *P* \< 0.05) of the obtained growth yield was observed, respectively, suggesting that PRL2010 is auxotrophic for cysteine. Furthermore, PRL2010 seems unable to grow on sulfate as its sole sulfur source, such as when this strain is grown in bCDM~PRL2010~ (a medium that contains MnSO~4~, MgSO~4~, and FeSO~4~).

Another reducing compound, glutathione, was added to bCDM~PRL2010~ and only very limited growth was detected when PRL2010 cells were cultivated for 24 h (OD600 value of 0.31 ± 0.038). Furthermore, we decided to investigate if taurine, which is a common nitrogen and sulfur sources present in the gut environment ([@B5]) influence the growth yields of PRL2010. However, we did achieved any significant grow (OD600 = 0.10 ± 0.01) of PRL2010 when taurine was used as the unique nitrogen and sulfur sources.

Assessing Cysteine Auxotrophy of Members of the Genus *Bifidobacterium*
-----------------------------------------------------------------------

We further investigated the behavior of other strains belonging to the *B. bifidum* species (see **Table [1](#T1){ref-type="table"}**), when cultivated under similar growth conditions (**Figure [2B](#F2){ref-type="fig"}**). These experiments showed that strains LMG11041, 156B, 85B, 324B, and LMG13195 were unable to grow on CDM~PRL2010~, (OD600 values ≤ 0.3) after 24 h of incubation (**Figure [2B](#F2){ref-type="fig"}**). The other *B. bifidum* strains investigated (i.e., LMG13200, LMG11582, and LMG11583) reached OD600 values of 0.7--0.9 and exhibited an identical auxotrophic behavior as PRL2010 for cysteine (**Figure [2B](#F2){ref-type="fig"}**).

Within the genus *Bifidobacterium*, the same auxotrophic behavior for cysteine appears to be widely distributed. In fact, of the currently recognized 48 (sub)species harboring the genus *Bifidobacterium*, only *B. boum* LMG10736, *B. minimum* LMG11592, *B. pullorum* LMG21816, *B. ruminantium* LMG21811, *B. saguini* DSM23967 and *B. scardovii* LMG21589 were shown to be able to grow in CDM~PRL2010~ without cysteine, though such strains reached OD600 values of just 0.5 ± 0.1 (**Figure [2C](#F2){ref-type="fig"}**). No bifidobacterial strain was able to grow in bCDM~PRL2010~.

Sulfur Amino Acid Metabolism of *B. bifidum* PRL2010
----------------------------------------------------

A general prediction based on genomic data about nitrogen metabolism within the genus *Bifidobacterium* was previously reported by ([@B25]). The presence of genes involved in amino acid biosynthesis appears to be conserved among the seven phylogenetic groups of the genus *Bifidobacterium* ([@B20]). However, the genes that are predicted to be involved in sulfur-containing amino acid metabolism were shown to be variably present within bifidobacterial genomes. In this context, an *in silico* analysis of the *B. bifidum* PRL2010 genome ([@B33]) for putative genes involved in sulfur-containing amino acid transport did not reveal any positive match.

Aliphatic sulfonates can be used as alternative sulfur sources for the synthesis of cysteine ([@B40]). Bioinformatics analyses revealed the occurrence of two genes (BBPR_0202 and BBPR_0362) encoding two putative ABC-type permeases, in the chromosome of PRL2010. A low level of homology with genes involved in sulfonate transport ([@B9]) was detected (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**), possibly explaining why *B. bifidum* PRL2010 cells are unable to grow with sulfate as the only sulfur source (bCDM condition, see **Figure [2A](#F2){ref-type="fig"}**). Another mechanism to achieve sulfur from the environment is based on the intake of cysteine by symporter proteins. This type of symporter may participate in the uptake of cysteine ([@B42]). In this context, a putative sodium dicarboxylate symporter gene (BBPR_0324) was identified in PRL2010 (see **Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). Moreover, two putative genes (BBPR_0668 and BBPR_0671) predicted to encode two carriers involved in glutamate transport system (GluA and GluD), exhibited 53 and 26% homology, respectively, with the genes that encode the [L]{.smallcaps}-cysteine uptake system of *B. subtilis* (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**).

As mentioned above, *B. bifidum* PRL2010 cells were shown to be unable to grow in presence of reduced glutathione (and in the absence of cysteine). Such physiological findings are in agreement with *in silico* analyses of PRL2010 chromosome sequences. In fact, the *pepT* and *pepM* genes, which are constituting the pathway for degradation of this compound ([@B2]) to generate cysteine, are absent in PRL2010 genome. Furthermore, a homolog of the *gshAB* gene, which specifies the glutamate--cysteine ligase/glutathione synthase, is also absent in chromosome of PRL2010 (**Figure [1](#F1){ref-type="fig"}**).

Genes predicted to be involved in the cysteine biosynthesis I/homocysteine degradation pathway and methionine biosynthesis I pathway were identified in PRL2010 (**Figure [3A](#F3){ref-type="fig"}**). *In silico* analyses of PRL2010 genome revealed the occurrence of the *cysE* (BBPR_1340) and *cysK* (BBPR\_ 1344) genes, which encode the predicted serine acetyltransferase that transfers an acetyl group to serine, and the cysteine synthase, respectively ([@B18]) (**Figure [3A](#F3){ref-type="fig"}**). In the same genomic region, we also identified the *metB* gene (BBPR_1343) predicted to encode a cystathionine-γ-synthase, which is catalyzing the conversion of cysteine to cystathionine, as well as the *luxS* gene (BBPR_1341), encoding an *S*-ribosylhomocysteinase involved in the production of homocysteine, and the *recQ* gene (BBPR_1342) encoding an ATP-dependent DNA helicase. When the presence of these genes was investigated in the genomes of other *B. bifidum* strains ([@B8]) included in this study, a high level of homology (higher than 98% at nucleotide level) was found. Furthermore, in the genome sequences of four *B. bifidum* strains, i.e., LMG13200, LMG13195, LMG11582, and LMG11583 ([@B8]), an additional acetyltransferase-encoding gene was identified (**Figure [3A](#F3){ref-type="fig"}**).

![**Schematic representation of genes involved in cysteine and methionine metabolism in *B. bifidum* species and transcriptional analysis in *B. bifidum* PRL2010.** **(A)** Shows the genetic map of the predicted cysteine/methionine metabolism gene region identified in the genome of *B. bifidum* PRL2010 and compared with other *B. bifidum* strains. Each individual gene is represented by an arrow and is colored or marked according to the predicted function as indicated in the figure. **(B)** Reports the relative transcription levels of cysteine and methionine metabolism genes from *B. bifidum* PRL2010 upon cultivation in complete CDM~PRL2010~, bCDM~PRL2010~ supplemented with cysteine (bCDM + Cys), bCDM~PRL2010~ supplemented with glutathione (bCDM + Glut), bCDM~PRL2010~ with cysteine and 2% (wt/wt) whey protein (bCDM + Whey) and bCDM~PRL2010~ with cysteine and 2% (wt/wt) casein hydrolysate as analyzed by quantitative real-time PCR assays. The histograms indicate the relative amounts of the *cysE, cysK, cysB, metA, metE, metB*, and *metC* genes mRNAs for the specific samples. The *y* axis indicates the logarithmic fold induction of the investigated gene compared to the reference condition (MRS). The *x* axis represents the different gene tested. Asterisks indicate statistically significant differences compared to the control. The error bar for each column represent the standard deviation calculated from three replicates.](fmicb-06-01331-g003){#F3}

Other genes such as the *cysB* gene (BBPR_0960), *metC* (BBPR_1226) and *metA* (BBPR_1654) that are predicted to be involved in cysteine and methionine metabolism ([@B11]; [@B18]) are scattered across the PRL2010 genome.

Growth Evaluation in Complex Substrates
---------------------------------------

The effects of complex substrates, such as whey proteins or casein hydrolysate, on PRL2010 growth were tested and are reported in **Figure [2D](#F2){ref-type="fig"}**. Whey proteins and casein hydrolysate were dissolved in CDM~PRL2010~ and bCDM~PRL2010~ with or without other nitrogen sources at 0.5 or 2% concentration (wt/wt), respectively. Casein hydrolysate better supports PRL2010 growth in presence of nitrogen, compared to what was observed when this strain was cultivated on whey proteins. In CDM or bCDM without other nitrogen sources, PRL2010 cells seemed to metabolize whey proteins more efficiently as displayed by the higher OD 600 values that were reached (**Figure [2D](#F2){ref-type="fig"}**).

Targeted Gene Expression Analyses of PRL2010 with Different Sulfur Substrate
----------------------------------------------------------------------------

Transcription of genes involved in sulfur metabolism, such as those of cysteine (*cysE, cysK* and *cysB*) and methionine metabolism (*met*A, *metE, metB*, and *metC*), were investigated using a qRT-PCR approach, the results of which are reported in **Figure [3B](#F3){ref-type="fig"}**.

When PRL2010 cells were cultivated in the complete CDM~PRL2010~, *cysB, cysE, cysK, metA* and *metB* were overexpressed (*P* \< 0.05) (**Figure [3B](#F3){ref-type="fig"}**). The occurrence of cysteine in the basal CDM~PRL2010~ (bCDM + Cys) does not seem to modulate expression of genes involved in sulfur amino acid metabolism. Glutathione (bCDM + Glut) does not allow a significant growth of PRL2010 (OD600 values of 0.31 ± 0.038). However, it enhanced the transcription of the *cysB*, *cysE*, *cysK, metA* and *metB* genes (*P* \< 0.05).

Regarding complex substrates, *cys* genes appear to be less induced when PRL2010 cells are cultivated in whey protein compared to basal CDM~PRL2010~ in the presence of casein hydrolysate (bCDM + Whey and bCDM + Casein respectively in **Figure [3B](#F3){ref-type="fig"}**), although at significant level (*P* \< 0.05). Moreover, casein hydrolysate significantly increases the transcription level of *metC*, the cystathionine β-liase (*P* \< 0.05).

In all conditions tested, no significant transcriptional changes were detected for the *metC* and *metE* genes predicted to encode for cystathionine β-liase and homocysteine methyltransferase, respectively, except for *metC* when PRL2010 was grown in bCDM~PRL2010~ with casein hydrolysate.

Discussion
==========

Following birth, the human intestine is rapidly colonized by a vast array of microorganisms. *Bifidobacterium*, and in particular, *B. bifidum* strains are abundant in breast-fed infants, due to their capacity to grow on mucin and on human milk oligosaccharides ([@B33]). The bifidogenic effect of breast milk due to bioactive peptides presence is well known ([@B17]). A similar bifidogenic effect was shown for milk-derived k-caseins with loss of activity when the disulfide bonds were oxidized ([@B29]).

Here, we investigated for the first time sulfur-containing amino acid metabolism in *B. bifidum* PRL2010 through the development of a CDM called CDM~PRL2010~ and by the molecular characterization of the putative auxotrophic behavior of this strain for cysteine. Data indicates that bCDM~PRL2010~ does not support *B. bifidum* PRL2010 growth, unless cysteine addition. The same behavior was extended to three other *B. bifidum* strains, i.e., LMG13200, LMG11582 and LMG11583. Furthermore, cysteine auxotrophy is not a common feature of all the (sub)species harboring the genus *Bifidobacterium*, since representatives of some species such as *B. boum, B. minimum, B. pullorum, B. ruminantium, B. saguini* and *B. scardovii* are able to grow without cysteine, although rather poorly.

*In silico* analyses of PRL2010 genome did not reveal the presence of the genetic arsenal needed to sulfate transport and reduction to sulfide. Growth experiments showed that cysteine is the only amino acid necessary to sustain PRL2010 growth but when the strain is cultivated in basal CDM~PRL2010~ with cysteine (bCDM + Cys) the transcription of genes involved in cysteine and methionine metabolism was not stimulated by the availability of these amino acid residues. Similar results were reported previously for other bacterial species, such as *Escherichia coli* ([@B15]), *Bacillus subtilis* ([@B21]), and *Lactococcus lactis* ([@B11]). Another reduced sulfur compound was used to understand if the role of cysteine in PRL2010 is linked to the reducing effect that it exploits on the redox potential ([@B9]). However, reduced glutathione does not sustain any appreciable strain growth, yet enhanced the transcription of genes predicted to be involved in sulfur amino acid metabolism (*cysB*, *cysE, cysK, metA* and *metB)*. Similar behavior was previously reported for *E. coli* ([@B15]) and *B. subtilis* ([@B21]).

Complex substrates from dairy industry such as whey proteins and casein hydrolysate act as a reservoir of amino acid, peptides and free protein. Transcriptional analysis showed that whey proteins and casein hydrolysate increased the transcriptions of genes involved in serine degradation and/or conversion to cysteine and methionine (*cysB*, *cysE, cysK metA* and *metB*).

Conclusion
==========

This study provides new insights into the amino acid utilization ability of the *B. bifidum* species. This work also suggested the existence of a relationship between the sulfur amino acid metabolism and the redox state of the cell. The use of complex nitrogen sources available in the infant gut revealed an enhancement of growth yield and expression of genes involved in sulfur amino acid metabolism in PRL2010. These results could open a new avenue of research for the development of novel functional foods based on milk caseins and whey proteins with high content of cysteine or cysteine precursor's compounds that could act as prebiotics for *Bifidobacterium* enrichment.
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